19th Biosimilars Congregation 2024

19th Annual Biosimilars Congregation 2024

“Uniting market leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”

11th December 2024 Hotel Kohinoor Continental Mumbai India

Virtue Insight is proud to announce that 19th Annual Biosimilars Congregation 2024 happening on 11th December 2024 Hotel Kohinoor Continental Mumbai India.

Please contact Email – [email protected] or Call - +91 44 24762472/ M: +91 9361957193

SPONSORSHIP:

Conference Sponsor & Exhibition Stall – Should you wish to Sponsor or purchase a Exhibition Stall (Booth) or a paid Speaker Slot you can simply email your interest and queries [email protected]

DELEGATE REGISTRATION:

Super Early Bird Discount Price (Valid till 18th Oct 2024) - INR 11000 + GST per delegate

Early Bird Discount Price (Valid till 19th Oct 2024 – 22nd Nov 2024) - INR 14000 + GST per delegate

Standard Price - INR 16000 + GST per delegate

KEY SPEAKERS:

SANJEEV GUPTA Sr. Vice President & Head Biosimilar Ipca Laboratories

SD SINHA Senior VP Development Hetero Labs

ABIR BANERJEE VP & Head R&D Biotech Bharat Serums and Vaccines

SANTOSH TAUR Director Medical Affairs Vaccines Rare Diseases & Digital Pfizer

MANNAN KHAMBATI Assistant VP Biotech Manufacturing Bharat Serums and Vaccines

SOURABH FULMALI Global Medical Director GSK

SANCHIT NANDA Senior Director Global Patient Solutions Gilead Sciences

AMARNATH SUGUMARAN Associate Director & Cluster Head Medical Affairs Cipla

UDAY HARLE Asst. VP/ Global Head Clinical Development Kashiv BioSciences

ABHISHEK SINHA Global Director - Regulatory Affairs Advanz Pharma

AKSHAYA ODAK Head - Regulatory Affairs (Biotech) Lupin

MILIND ANTANI Leader Pharma and Healthcare Nishith Desai Associates

PRITHWIJIT KUNDU CMO - NCE NDD Wockhardt

PANKAJ THAKUR GM Clinical Project Management - Drug Discovery Biologics Hetero Labs

DATTATRAY PAWAR Head Medical Affairs - Deputy GM Alkem Laboratories

SEEMA BHANDARKAR Global Program Manager Biosimilar Operations Biocon

UMA SINHA DATTA Director PDS India Cytiva

SANJAY B. NIRANJAN Assistant Director Bioassay Development (Biosimilars) Lupin

ANURAG TIWARI AVP R&D Zumutor Biologics

KAVITA LAMROR Partner RWE & Digital Transformation Maxis Clinical Sciences

ROSHAN PAWAR Head Medical Affairs Alkem Laboratories

SAMIR KULKARNI Head - DBT ICT Center Institute Of Chemical Technology

SWEETY MATHEW Regulatory Professional- Global Regulatory Affairs: CMC Rare Diseases Novo Nordisk

RANJIT BARSHIKAR CEO QBD International United Nations Adviser

SHALU KASLIWAL Group Lead - Medical Sciences Biologics Dr. Reddy's Laboratories

APARNA PRABHUNE Asst GM Regulatory Affairs Wockhardt

KHOKAN DEBNATH Sr GM/(Head) – Regulatory Affairs Clinical Operations PV & QA (India & Emerging Market) Wockhardt

VISHWAS SOVANI Founder Director Pharmawisdom

Plus more joining soon

KEY THEMES DISCUSSED:

Integrated approach to biosimilar development & commercialization

Current trends and strategies to access biosimilar market

Innovative clinical approach in biosimilars & Clinical development of biosimilars

Factors that drive the selection of a biosimilar asset

Imperatives for R&D in biosimilars - Entering the next wave of growth

Addressing developmental challenges to maximize biosimilars market growth

Global Perspectives: Impact of Biosimilars around the world – What have we learned so far?

Market Access - Implications for product launch and market exclusivity

Commitment to Quality - Excellence in manufacturing biosimilars

Overcoming Barriers to the Market Access of Biosimilars

Who can influence payers on Biosimilar decision making

What type of evidence will be needed for registering Biosimilars in the future?

Outlining what investors wish inventors knew before coming to the table

RWE - What type of evidence will be needed for registering Biosimilars in the future?

Ensuring the balance between product development and patient safety

Technology: Unlocking the better ways

Regulatory - The evolving regulatory framework for biosimilar approvals

What comes next for the biosimilars market?

Be part of a major networking opportunity

WHO SHOULD ATTEND AND WHO YOU’LL MEET:

CSOs CMOs Vice Presidents Presidents Heads Directors Team Leaders and Senior Scientists from the following roles:

Biopharmaceuticals/ Biotherapeutics Follow on Biologics/Follow on Proteins Biologics/Biotechnology/ Bio generics Legal Affairs Intellectual Property Health Economics Pricing and Reimbursement Clinical Immunology Principal Scientist Chief Scientific Officer Process Control and Analytical Technologies Analytical Characterisation Regulatory Quality Affairs/ Quality Control New Product Development Process Science Portfolio Management Research & Development Business Development Business Operations Scientific Affairs Commercial Affair

Host or Publisher Virtue Insight